Digital disruption has reached Life Sciences & Healthcare, and with it comes an imperative for Life Sciences companies to transform their core technology and leverage data and analytics to gain a competitive advantage.
Break down organizational silos to deliver patient centric innovation
Business success is driven to a great extent by the creation of new revenue streams (i.e. innovation) and operational excellence. To achieve this Life Sciences companies must implement a digitalization imperative – leveraging state-of-the-art technologies to capitalize on the data, knowledge, and know-how contained within their value networks to innovate and deliver at speed.
Organizations that transform their businesses by embracing the principles and technology that deliver digital continuity and facilitate data sharing across the entire value network, generating synergies that drive innovation and leveraging existing know-how to deliver differentiated patient experiences will win.
It will transform the way they innovate and operate, driving significantly enhanced margins with patient-centric experiences and increased productivity and profits.
Maximize ecosystem engagement to:
Speed up development time to increase market share and revenue
Improve value creation from collaborative business models
Improve organization efficiency
Increase manufacturing operational efficiency and yield
See how Integrated Evidence provides stronger insights, confident decision-making, and increases the probability of clinical trial success.
Collaborative scientific innovation enhances the virtual workspace with new mobile applications and tools, leveraging social communication to maximize value network engagement for a more holistic collaboration and digital transformation strategy.
The 3DEXPERIENCE® platform accelerates collaboration and scientific innovation enabling Life Sciences companies to better manage complexity and change and create superior therapeutic experiences in one virtual environment. With transformed collaboration, unparalleled access to knowledge and know-how, data and data analytics, and the ability to make better-informed decisions with full visibility across their internal and external ecosystems, the 3DEXPERIENCE platform truly drives sustainable innovation in Life Sciences companies.
With our MEDIDATA solutions, using data science to enable frontline decision-makers with actionable, data-driven insights, Life Sciences companies can improve the speed, quality, and success of their clinical trials but also move to the future by designing Synthetic Control Arms for their studies.
“As a result of breakthroughs in data analysis, we stand on the verge of a life sciences industry powered not by trial and error, but by a virtuous cycle of experimental evidence that brings new insights, new applications, new refinements and new successes.” Glen de Vries: Co-Founder and Co-CEO, Medidata, a Dassault Systèmes company
IDMP compliance requires that the information sent to regulatory agencies be consistent in format and ISO coding. This provides a significant opportunity beyond compliance: digital continuity can provide a competitive advantage to your pharmaceutical organization.
Learn how Synthetic Controls are enabling new insights for oncology clinical development and streamlines clinical development and mitigates Go/No-go decision risk. Synthetic Control Data can assist disease learning and future trial planning, and Synthetic Control Arm provides precise data for confident interpretation of uncontrolled trials.
Bristol-Myers Squibb ELN is a critical first step rather than a magic bullet. Implementing an ELN enables organizations to begin to centralize electronic data and identify legacy tasks and processes that are unnecessary in an electronic workflow.
The transition from paper-based systems to electronic ones is the most productive transition we will make as an industry.
Discover Dassault Systèmes®' Life Sciences industry solutions aiming to improve patient and physician experience, and organizational business excellence.